Body Recomposition With Peptides: A Realistic Look
Body recomposition with peptides is mostly a story about expectations. Recomposition (losing fat while holding or building muscle) is driven overwhelmingly by resistance training, adequate protein, and recovery, and the research peptides marketed for it have thin human evidence at best. The realistic verdict: lead with the proven fundamentals, and treat any provider-directed peptide as a small, unproven, trackable experiment rather than a shortcut.
What Body Recomposition Actually Means
Body recomposition, or "recomp," means changing the ratio of fat mass to lean mass, typically losing fat while holding or gaining muscle, rather than simply changing total bodyweight. It is the reason two people at the same weight can look and perform completely differently.
The key consequence for anyone evaluating peptides is that recomposition is invisible on the scale. If you lose four pounds of fat and gain two pounds of muscle, the scale moves two pounds, which understates what happened. This is exactly why measurement matters so much in this topic, a point we return to at the end.
The Proven Base: Training, Protein, and Recovery
Before any peptide enters the conversation, the foundation has to be in place, because the foundation is where almost all of the result comes from.
Resistance training is the single most important driver. It is the signal that tells your body to preserve and build muscle, especially in a calorie deficit where the body would otherwise be willing to give up lean tissue. The same principle applies whether you are dieting normally or losing weight on a medication, which is why resistance training on a GLP-1 is framed as the number-one muscle-preservation lever in that context too.
Adequate protein is the raw material. A commonly cited evidence-based target for preserving muscle in a deficit is roughly 1.6 grams of protein per kilogram of bodyweight per day, give or take, spread across the day. Without enough protein, the training signal has nothing to build with.
Recovery and sleep govern how well your body responds to the training stimulus and manages the hormones involved in muscle maintenance. Chronic under-sleeping blunts results no matter what else you do.
These three are not the boring prelude to the interesting peptide section. They are the reason recomposition happens at all. Any honest ranking of recomposition drivers puts them first by a wide margin.
Where Peptides Are Claimed to Fit
The peptides marketed for recomposition fall mostly into the growth-hormone category. The shared theory is that raising growth hormone (GH) and insulin-like growth factor 1 (IGF-1) should nudge the body toward building muscle and mobilizing fat. The biology is plausible. The human evidence that this produces meaningful recomposition is the weak link.
A few of the commonly discussed options:
- CJC-1295 and ipamorelin (often stacked): GH-axis peptides that raise GH and IGF-1. Human evidence is limited and mostly mechanistic, and both are not FDA-approved.
- MK-677 (ibutamoren): an orally active GH secretagogue (technically not a peptide) with more human data than most. Its best controlled trial is instructive, and we cover it below.
- Tesamorelin: a GHRH analog that is actually FDA-approved, but only for HIV-associated visceral fat, with off-label recomp use lacking equivalent evidence.
For the deeper version of this comparison, the GH peptides for body recomposition article goes claim by claim.
Hype vs Evidence: What the Research Supports
The most useful single data point comes from MK-677. In the best-designed trial available (Nass et al., Annals of Internal Medicine, 2008), 25 mg per day for 12 months in 65 healthy older adults increased lean mass by about 1.1 kg, but it also increased body weight by about 1.5 kg (some of that fat), produced no improvement in muscle strength or functional outcomes, and raised fasting glucose while worsening insulin sensitivity. In other words: a measurable lean-mass number, but no strength or function benefit, plus metabolic downsides.
That pattern, "raises a hormone or a lean-mass figure but does not deliver the outcome people actually want," is the recurring theme. For CJC-1295, published human data (Walker et al., Journal of Clinical Endocrinology and Metabolism, 2006, n=65) shows it raises GH and IGF-1, but there are no combination recomposition trials demonstrating a body-composition payoff in healthy adults. For tesamorelin, the strong RCT evidence is a roughly 15-18% reduction in visceral adipose tissue in HIV-associated lipodystrophy (the FDA-approved indication), which is fat-specific and does not transfer automatically to general muscle building.
The bottom line the evidence supports: growth-hormone peptides reliably move hormone numbers, but the recomposition payoff in humans is small, inconsistent, or unmeasured.
Ranking the Drivers of Recomposition
Here is an honest ranking of what actually changes your fat-to-muscle ratio, by evidence strength and typical effect size. This is educational, not a protocol, and it deliberately puts the unproven options last.
| Driver | Evidence strength | Effect on recomposition | Notes |
|---|---|---|---|
| Resistance training | Strong (human RCTs) | Large | The core signal to preserve and build muscle; non-negotiable |
| Adequate protein (~1.6 g/kg) | Strong (human RCTs) | Large | Raw material for muscle; matters most in a deficit |
| Recovery and sleep | Strong (human evidence) | Moderate to large | Governs response to training and hormonal balance |
| Tesamorelin (fat only) | Moderate, narrow population | Moderate for visceral fat, not muscle | FDA-approved only for HIV lipodystrophy; off-label use unproven |
| GH peptides (CJC-1295, ipamorelin) | Weak/preclinical in humans | Small or unproven | Not FDA-approved; raise GH/IGF-1, recomp payoff unestablished |
| MK-677 (ibutamoren) | Limited human; mixed | Small lean-mass change, no strength gain | Best trial showed no functional benefit; raised glucose |
The shape of this table is the whole point. The top three are where recomposition is won; the bottom three are, at best, small adjuncts a provider might consider, and several carry real downsides and unresolved regulatory status.
The Regulatory and Safety Reality
Most of the peptides in the recomp conversation are not FDA-approved. BPC-157, TB-500, GHK-Cu, semax, and epitalon were removed from the FDA's Category 2 compounding list in April 2026, but that does not mean they are approved or freely compoundable; a Pharmacy Compounding Advisory Committee (PCAC) review is scheduled for July 2026, and the status is actively evolving (check FDA.gov for the current determination). CJC-1295 and ipamorelin are in a worse position: the PCAC voted against them in late 2024, so they have no clear path to legal 503A compounding. Tesamorelin (Egrifta) and bremelanotide (Vyleesi) are the rare FDA-approved members of this broader space, each for a narrow indication.
There are two safety layers worth holding onto. First, the WADA 2026 Prohibited List bans all of the GH secretagogues and GHRH analogs (CJC-1295, ipamorelin, tesamorelin, MK-677) at all times, which matters if you compete. Second, products sold as "research chemicals" are not reviewed for purity, sterility, or endotoxin content, so contamination and misdosing are genuine risks. This is education, not medical advice; any peptide protocol should be directed and monitored by a licensed clinician who can review your labs, history, and goals.
How to Prove It: Measure, Do Not Guess
Because recomposition is invisible on the scale, the only way to know whether a plan is working, with or without a peptide, is to measure fat mass and lean mass over time. A DEXA scan is the common reference standard; bioelectrical impedance devices (InBody, smart scales) are less precise in absolute terms but useful for trends; strength benchmarks and tape measurements are free proxies anyone can track weekly. The deeper method comparison lives in body composition tracking on a GLP-1.
This is Myo's home turf. Myo, an iOS app by PixelPort LLC, is built to track fat-versus-muscle alongside protein intake and resistance-training sessions in one place, which is exactly the combination that turns "I think the peptide is recomping me" into a measured before-and-after. If a provider directs a peptide protocol, Myo logs each injection, site, and vial next to the body-composition trend, so any effect (or lack of one) shows up in the data rather than the mirror. Myo is a tracking and education tool only; it does not prescribe, source, or recommend doses.
The realistic takeaway: build recomposition on training, protein, and recovery, keep any provider-directed peptide in its proper place as a small and unproven adjunct, and measure relentlessly so you are judging results against weeks of data instead of hope.
References
Nass R et al., Annals of Internal Medicine (2008) Twelve-month randomized trial of MK-677 (ibutamoren) in healthy older adults; reported lean-mass change but no strength or functional benefit and worsened glucose metabolism. https://www.opss.org/article/performance-enhancing-substance-mk-677-ibutamoren
Walker RF et al., Journal of Clinical Endocrinology and Metabolism (2006) Phase I/II human data on CJC-1295 showing dose-dependent increases in GH and IGF-1; small sample, no body-composition outcome trials. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
FDA: Egrifta (tesamorelin) Approval and Indication FDA-approved indication for tesamorelin is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy; off-label recomposition use is not FDA-approved. https://www.contagionlive.com/view/fda-approves-f8-formulation-of-theratechnologies-tesamorelin-for-hiv-associated-lipodystrophy
FDA PCAC Calendar: July 23-24, 2026 Meeting Pharmacy Compounding Advisory Committee meeting at which several research peptides are scheduled for review; status of compounding eligibility is pending. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
WADA 2026 Prohibited List World Anti-Doping Agency list prohibiting GH secretagogues and GHRH analogs (including CJC-1295, ipamorelin, tesamorelin, and MK-677) at all times. https://www.wada-ama.org/en/prohibited-list
Endocrine Society: Testosterone and Body Composition Context Clinical guidance noting that diet and resistance training remain primary drivers of body composition even when hormone-axis therapies are used. https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy
Frequently asked questions
Can peptides help you build muscle and lose fat at the same time?
There is no strong human evidence that research peptides meaningfully drive simultaneous muscle gain and fat loss on their own. Growth-hormone peptides raise GH and IGF-1, but the leap from raising those hormones to a measurable recomposition advantage is where the evidence thins out, and most of it is preclinical or anecdotal. The reliable drivers of recomposition remain resistance training, adequate protein, and recovery. Any peptide is best understood as a small, unproven adjunct that a licensed provider should oversee.
How much does recomposition with peptides realistically change your body?
Honestly, far less than marketing implies. For the growth-hormone peptides commonly discussed for recomp, robust human body-composition data is largely absent, so a realistic expectation is a small effect at most, layered on top of the training and protein that do the real work. Tesamorelin has genuine visceral-fat-reduction data, but that is fat-specific, off-label outside its HIV indication, and not evidence of muscle building. Expect modest, individual, and hard-to-isolate results.
Which peptides are used in a recomp stack?
People commonly discuss growth-hormone secretagogues such as CJC-1295 and ipamorelin, the oral compound MK-677 (ibutamoren), and tesamorelin in a recomposition context. Most of these are not FDA-approved, are sold as research chemicals, and are banned in sport by WADA. Stacking multiple unapproved compounds multiplies the unknowns around purity, interactions, and dosing. None of this should be self-directed; a licensed clinician is the only appropriate source of guidance.
Do you still need training and protein with peptides?
Yes, and they are the part that actually works. Resistance training is the signal that tells your body to keep or build muscle in a calorie deficit, and adequate protein is the raw material. No peptide replaces either; at best a provider-directed peptide sits on top of those fundamentals. If the training and protein are not in place, a peptide is unlikely to produce the recomposition people are hoping for.
How do you measure recomposition?
Because the scale cannot separate fat from muscle, you need a body-composition method: a DEXA scan (the common reference standard), a bioelectrical impedance device such as an InBody or smart scale, or at minimum strength benchmarks and tape measurements tracked consistently. Compare readings several weeks apart rather than chasing single measurements. Tracking fat mass and lean mass over time is the only way to know whether a recomposition plan, with or without a peptide, is doing anything.
Keep reading
GH Peptides for Body Recomposition: Hype vs Evidence
Do GH peptides actually recomp your body? An honest look at growth-hormone peptides for muscle and fat, what evidence supports the claims, and what is.
Best Peptides for Muscle: Evidence-Ranked
Best peptides for muscle, evidence-ranked: what GH peptides, secretagogues, and others can and can't do for muscle, and why training and protein still win.
Best Peptides for Fat Loss: What's Studied vs What's Hyped
Best peptides for fat loss, evidence-ranked: where tesamorelin, GH peptides, and others stand vs the hype, and how they compare to GLP-1 drugs for weight loss.